^
    Back
    Association details:
    Biomarker:MUC2 negative
    Cancer:Ampulla of Vater Carcinoma
    Drug:gemcitabine (DNA synthesis inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Surgery
    Title:

    Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater

    Published date:
    07/01/2015
    Excerpt:
    Via a prospective database, 112 PapCa were identified...PT patients receiving adjuvant gemcitabine chemotherapy featured improved OS (32 vs 13 months; P = .013), whereas gemcitabine tended to be associated with decreased OS in IT patients (35 vs 112 months; P = .193)....PT patients with CK7-positivity or MUC2-negativity were segregated into an even poorer prognostic group.
    DOI:
    10.1016/j.surg.2015.02.001